Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endometrium Tumor Clear all
Completed Not applicable Interventional

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

NCT03372720
View directory record Official record
Conditions
Cervical Carcinoma, Dyspareunia, Endometrial Carcinoma, Ovarian Carcinoma, Vaginal Carcinoma, Vaginal Dryness, Vulvar Carcinoma
Interventions
Laser Therapy, Questionnaire Administration, Sham Intervention
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

NCT00050440
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 28, 2026, 7:14 PM EDT
Recruiting Phase 1 Interventional

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

NCT07503808
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Interventions
IDE034
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

NCT03849469
View directory record Official record
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 28, 2026, 7:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sacituzumab govitecan-hziy, Doxorubicin, Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
57
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives

NCT04257045
View directory record Official record
Conditions
Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation, Deleterious STK11 Gene Mutation, Endometrial Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions
Interview, Questionnaire Administration, Survey Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 28, 2026, 7:14 PM EDT
Active, not recruiting Phase 1 Interventional

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT03860272
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Terminated Phase 2 Interventional Results available

Trisenox® in Women With Metastatic Endometrial Cancer

NCT01184053
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Arsenic trioxide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Not applicable Interventional Results available

Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging

NCT01673022
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer
Interventions
IC Green
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
7
States / cities
Mobile, Alabama • Indianapolis, Indiana • Edgewood, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers

NCT04626895
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT00003691
View directory record Official record
Conditions
Endometrial Cancer
Interventions
filgrastim, cisplatin, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Sep 28, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance

NCT00581646
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Leukemia, Non-Hodgkin's Lymphoma, Uterine Cancer, Vaginal Cancer, Infertility
Interventions
survey instrument
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 28, 2026, 7:14 PM EDT
Not listed Phase 2 Interventional

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

NCT03935256
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin and Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Marywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 28, 2026, 7:14 PM EDT
Recruiting No phase listed Observational

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

NCT05051722
View directory record Official record
Conditions
Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Interventions
Vaginal Fluid Collection, Blood Collection
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
3,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
24
States / cities
Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

NCT06620029
View directory record Official record
Conditions
Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Interventions
BMX-001, Paclitaxel (Taxol)
Drug
Lead sponsor
BioMimetix JV, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 28, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional

A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

NCT05194072
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
Interventions
Felmetatug Vedotin, Pembrolizumab
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Aurora, Colorado • Denver, Colorado • Celebration, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors

NCT01806350
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Uterine Sarcoma, Vulvar Cancer
Interventions
questionnaire administration, standard follow-up care, educational intervention
Other · Procedure
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 28, 2026, 7:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

NCT00495235
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
8
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

NCT03617679
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Rucaparib, Placebo Oral Tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

NCT00513786
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin, Paclitaxel, bevacizumab
Drug
Lead sponsor
David O'Malley
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

NCT00315861
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer
Interventions
pemetrexed, topotecan
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Phase 2 Interventional Results available

Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer

NCT04719273
View directory record Official record
Conditions
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
Interventions
Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment, Questionnaire Administration, Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive), Progesterone Receptor Positive ( PGR Positive; PR Positive)
Drug · Other · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Abington, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 28, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Self-Advocacy Serious Game in Advanced Cancer

NCT03339765
View directory record Official record
Conditions
Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Breast Cancer Stage IV, Cervical Cancer Stage IIIB, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB, Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Vulvar Cancer, Stage III, Vulvar Cancer, Stage IV, Vaginal Cancer Stage III, Vaginal Cancer Stage IVA, Vaginal Cancer Stage IVB
Interventions
Strong Together serious game
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 4, 2023 · Synced Sep 28, 2026, 7:14 PM EDT